Related references
Note: Only part of the references are listed.Incidence of Listeriosis and Related Mortality Among Groups at Risk of Acquiring Listeriosis
Veronique Goulet et al.
CLINICAL INFECTIOUS DISEASES (2012)
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
D. Salmon-Ceron et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy
J. M. Ramos et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2011)
Listeria endocarditis in a patient with psoriatic arthritis on infliximab: Are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?
Theodoros Kelesidis et al.
JOURNAL OF INFECTION (2010)
Risk Factors, Clinical Features, and Outcomes of Listeriosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study
Nuria Fernandez-Sabe et al.
CLINICAL INFECTIOUS DISEASES (2009)
Listeriosis: a primer
Robert Bortolussi
CANADIAN MEDICAL ASSOCIATION JOURNAL (2008)
Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease
Ferenc Izbeki et al.
INFLAMMATORY BOWEL DISEASES (2008)
Listeria infections associated with infliximab:: case reports
Thomas Kesteman et al.
CLINICAL RHEUMATOLOGY (2007)
Serious adverse events with infliximab: Analysis of spontaneously reported adverse events
Richard A. Hansen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2006)
Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept?
S Ehlers
CLINICAL INFECTIOUS DISEASES (2005)
Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy
B Popa et al.
CYTOKINE (2005)
Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection
BM Saunders et al.
JOURNAL OF IMMUNOLOGY (2005)
Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
RS Wallis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2005)
Listeria meningitis associated with infliximab
VL Bowie et al.
ANNALS OF PHARMACOTHERAPY (2004)
Infliximab in inflammatory bowel disease:: clinical outcome in a population based cohort from Stockholm County
T Ljung et al.
GUT (2004)
Granulomatous infectious diseases associated with tumor necrosis factor antagonists
RS Wallis et al.
CLINICAL INFECTIOUS DISEASES (2004)
Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy -: Association with decreased interferon-γ production and toll-like receptor 4 expression
MG Netea et al.
ARTHRITIS AND RHEUMATISM (2003)
Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection:: comment on the letter by Gluck et al
AG Aparicio et al.
ARTHRITIS AND RHEUMATISM (2003)
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents
NR Slifman et al.
ARTHRITIS AND RHEUMATISM (2003)
Anti-tumor necrosis factor therapy and Listeria monocytogenes infection:: report of two cases
T Glück et al.
ARTHRITIS AND RHEUMATISM (2002)
Binding and functional comparisons of two types of tumor necrosis factor antagonists
B Scallon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Listeria meningitis after treatment with infliximab
BM Kamath et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2002)
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology
VP Mohan et al.
INFECTION AND IMMUNITY (2001)
Share Paper
